Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fecal microbiota transplant-University of Alberta
- Development stage
- Discontinued
- Lead developer
- University of Alberta
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Rectal, Oral
01
Overview
Fecal microbiota transplant (FMT) developed by the University of Alberta is a microbiome-based biologic therapy investigated for the treatment of mild-to-moderate Crohn's disease. The active ingredient consists of the complete fecal microbiota from screened healthy donors, which includes a diverse range of bacteria and other microorganisms. The therapy's proposed mechanism of action is to restore healthy gut microbial diversity and composition in patients with Crohn's disease, thereby correcting the characteristic dysbiosis, reducing inflammation, and re-establishing microbial homeostasis. The treatment was administered via an initial colonoscopy followed by weekly oral capsules for 7 weeks. [3, 5] A multicenter, double-blind, placebo-controlled trial (NCT03078803), conducted in collaboration with the University of Calgary and McMaster University, was terminated early for futility after the therapy failed to meet its primary endpoint of inducing clinical and endoscopic remission. [3, 4, 5]
- Other names
- fecal microbiota transplantFMT
Beyond the preview
Go deeper on fecal microbiota transplant-University of Alberta.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fecal microbiota transplant-University of Alberta.